-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ZimVie (NASDAQ:ZIMV) Now Covered by Analysts at Barclays
ZimVie (NASDAQ:ZIMV) Now Covered by Analysts at Barclays
Barclays assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a report released on Wednesday morning, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
ZimVie Stock Performance
NASDAQ:ZIMV opened at $8.21 on Wednesday. The stock has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.42. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. ZimVie has a 12-month low of $6.67 and a 12-month high of $50.40.
Get ZimVie alerts:ZimVie (NASDAQ:ZIMV – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The firm had revenue of $214.58 million during the quarter, compared to analysts' expectations of $214.83 million. On average, sell-side analysts expect that ZimVie will post 1.95 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ZimVie
A number of large investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new stake in shares of ZimVie in the third quarter valued at approximately $27,000. US Bancorp DE purchased a new position in shares of ZimVie during the third quarter worth $36,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of ZimVie during the third quarter worth $46,000. Strs Ohio acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of ZimVie in the third quarter valued at $47,000. Institutional investors and hedge funds own 74.62% of the company's stock.About ZimVie
(Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Featured Articles
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
Barclays assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a report released on Wednesday morning, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
据The Fly报道，巴克莱在周三上午发布的一份报告中对ZimVie(纳斯达克：ZIMV-GET评级)的股票进行了报道。该经纪公司对该股发布了减持评级和9.00美元的目标价。
ZimVie Stock Performance
ZimVie股票表现
NASDAQ:ZIMV opened at $8.21 on Wednesday. The stock has a 50-day moving average price of $8.65 and a 200 day moving average price of $13.42. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. ZimVie has a 12-month low of $6.67 and a 12-month high of $50.40.
纳斯达克：ZIMV周三开盘报8.21美元。该股的50日移动均线价格为8.65美元，200日移动均线价格为13.42美元。该公司的流动比率为2.51，速动比率为1.48，债务权益比率为0.76。ZimVie的12个月低点为6.67美元，12个月高位为50.40美元。
ZimVie (NASDAQ:ZIMV – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The firm had revenue of $214.58 million during the quarter, compared to analysts' expectations of $214.83 million. On average, sell-side analysts expect that ZimVie will post 1.95 earnings per share for the current fiscal year.
津维(纳斯达克：ZIMV-GET评级)上一次公布财报是在11月9日星期三。该公司公布本季度每股收益为0.49美元，比分析师普遍预期的0.27美元高出0.22美元。ZimVie的净资产回报率为负2.75%，净利润率为负9.96%。该公司本季度营收为2.1458亿美元，高于分析师预期的2.1483亿美元。卖方分析师平均预计，ZimVie本财年每股收益将达到1.95美元。
Hedge Funds Weigh In On ZimVie
对冲基金对ZimVie的看法
About ZimVie
关于ZimVie
(Get Rating)
(获取评级)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
ZimVie公司是一家医疗技术公司，开发、制造和提供一系列产品和解决方案，旨在治疗一系列脊柱疾病，并在全球范围内支持牙齿替换和修复程序。它提供牙科植入系统、假体和基台产品、手术器械和套件；骨移植、屏障膜、同种异体移植和胶原伤口护理产品；口腔内扫描仪；虚拟治疗计划服务、指导性手术解决方案、CAD/CAM工作流程系统、患者特定的修复部件和口腔内扫描仪，以及用于各种脊柱程序、生物制剂和骨愈合技术的脊柱融合植入物和器械。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免费获取StockNews.com关于ZimVie的研究报告(ZIMV)
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
- 机构将Rite Aid的股票跌至谷底
- 这就是为什么你应该避开联邦快递的反弹
- 维京治疗公司股票为何暴涨
- 耐克公司业绩和前景走高
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
接受ZimVie Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ZimVie和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧